유방암 액체생검 시장 : 바이오마커별, 최종사용자별 - 세계 전망(2025-2030년)

The Breast Cancer Liquid Biopsy Market was valued at USD 494.29 million in 2023, expected to reach USD 589.92 million in 2024, and is projected to grow at a CAGR of 19.44%, to USD 1,714.15 million by 2030.

The breast cancer liquid biopsy market is a rapidly evolving sector focused on minimally invasive tests enabling early cancer detection, monitoring, and personalized treatment. This method involves analyzing circulating tumor DNA (ctDNA) in a patient's blood, offering a comprehensive view of tumor dynamics. Key factors driving its necessity include the increasing global prevalence of breast cancer and the limitations of traditional biopsies, such as invasiveness and potential complications. Applications of liquid biopsy span from early detection to monitoring treatment efficacy and identifying potential relapse, thus enhancing precision and personalization in patient care. End-use segments primarily include hospitals, diagnostic laboratories, and research institutes.

Market growth is influenced by technological advancements in genomics and precision medicine, increasing awareness of early cancer detection benefits, and a shift towards non-invasive diagnostic techniques. Potential opportunities lie in emerging markets, where increasing healthcare expenditure and heightened awareness amplify growth prospects. Additionally, partnerships between biotech firms and research institutions could accelerate innovation and improve accessibility to these advanced diagnostics. However, challenges remain in the form of high costs, regulatory hurdles, and limited sensitivity compared to traditional tissue biopsies, potentially restraining market expansion.

The best areas for innovation include improving the sensitivity and specificity of liquid biomarker detection techniques and integrating artificial intelligence to enhance predictive analytics and interpretation of liquid biopsy data. Research focused on multi-cancer early detection and the exploration of new biomarkers could provide competitive advantages. The market is highly dynamic and fragmented with strong competition among established players and rising startups, making it crucial for companies to invest in R&D and strategic collaborations. Businesses should focus on optimizing cost structures and simplifying regulatory pathways to enhance adoption rates. In a market characterized by rapid technological updates and regulatory complexities, agility and foresight in strategic planning are vital for sustaining competitive advantage and fostering growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Breast Cancer Liquid Biopsy Market

The Breast Cancer Liquid Biopsy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising prevalence of breast cancer worldwide
  • Increasing demand for non-invasive breast cancer treatment
  • Availability of funding for liquid biopsy R&D
• Market Restraints
  • High cost of breast cancer liquid biopsy
• Market Opportunities
  • Technological advancements in early-stage detection of breast cancer liquid biopsy
  • Increasing breast cancer liquid biopsy reagent approvals
• Market Challenges
  • Stringent regulatory issues and poor reimbursement policies

Porter's Five Forces: A Strategic Tool for Navigating the Breast Cancer Liquid Biopsy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Breast Cancer Liquid Biopsy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Breast Cancer Liquid Biopsy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Breast Cancer Liquid Biopsy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Breast Cancer Liquid Biopsy Market

A detailed market share analysis in the Breast Cancer Liquid Biopsy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Breast Cancer Liquid Biopsy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Breast Cancer Liquid Biopsy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Breast Cancer Liquid Biopsy Market

A strategic analysis of the Breast Cancer Liquid Biopsy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Breast Cancer Liquid Biopsy Market, highlighting leading vendors and their innovative profiles. These include Adaptive Biotechnologies Corporation, Bio-Rad Laboratories, Inc., Biocept, Inc., Biodesix, Inc., Epic Sciences Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Fluxion Biosciences Inc., Guardant Health, Inc., Illumina, Inc., Johnson & Johnson Services, Inc., NeoGenomics Laboratories, Inc., Qiagen N. V. by Thermo Fisher Scientific Inc., Sysmex Corporation, and The Menarini Group.

Market Segmentation & Coverage

This research report categorizes the Breast Cancer Liquid Biopsy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Biomarker, market is studied across Cell-free DNA, Circulating Tumor Cells, and Extracellular Vesicles.
• Based on End-User, market is studied across Hospitals & Physician Laboratories and Reference Laboratories.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising prevalence of breast cancer worldwide
    • 5.1.1.2. Increasing demand for non-invasive breast cancer treatment
    • 5.1.1.3. Availability of funding for liquid biopsy R&D
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of breast cancer liquid biopsy
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in early-stage detection of breast cancer liquid biopsy
    • 5.1.3.2. Increasing breast cancer liquid biopsy reagent approvals
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory issues and poor reimbursement policies
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Breast Cancer Liquid Biopsy Market, by Biomarker

• 6.1. Introduction
• 6.2. Cell-free DNA
• 6.3. Circulating Tumor Cells
• 6.4. Extracellular Vesicles

7. Breast Cancer Liquid Biopsy Market, by End-User

• 7.1. Introduction
• 7.2. Hospitals & Physician Laboratories
• 7.3. Reference Laboratories

8. Americas Breast Cancer Liquid Biopsy Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Breast Cancer Liquid Biopsy Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Breast Cancer Liquid Biopsy Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Adaptive Biotechnologies Corporation
• 2. Bio-Rad Laboratories, Inc.
• 3. Biocept, Inc.
• 4. Biodesix, Inc.
• 5. Epic Sciences Inc.
• 6. Exact Sciences Corporation
• 7. F. Hoffmann-La Roche Ltd.
• 8. Fluxion Biosciences Inc.
• 9. Guardant Health, Inc.
• 10. Illumina, Inc.
• 11. Johnson & Johnson Services, Inc.
• 12. NeoGenomics Laboratories, Inc.
• 13. Qiagen N. V. by Thermo Fisher Scientific Inc.
• 14. Sysmex Corporation
• 15. The Menarini Group